Almont, 10 mg 98 pcs.

Bronchospasm, Bronchial asthma, Runny nose (rhinitis)

Prevention and long-term treatment of bronchial asthma in children, including:

• preventing daytime and nighttime symptoms of the disease (for children 2 years and older);
• Treatment of bronchial asthma in patients with hypersensitivity to acetylsalicylic acid (for children 6 years and older);
• preventing exercise-induced bronchospasm (for children 2 years and older).

Promotion of symptoms of seasonal and year-round allergic rhinitis in children from 2 years of age.

Active ingredient

Composition

How to take, the dosage

Therapeutic effect of the drug ALMONT, allowing to control asthma symptoms, is achieved within 24 hours after intake. The patient is recommended to continue taking the drug both during periods of controlled bronchial asthma and during exacerbation of bronchial asthma.

The drug ALMONT should not be taken together with other drugs containing the same active ingredient, montelukast.

Elderly patients, patients with renal impairment and patients with mild to moderate hepatic impairment do not require special dose adjustments.

There is no need to adjust the dose depending on the gender of the patient.

There are no data on the use of montelukast in patients with severe hepatic impairment.

The drug ALMONT can be added to a patient’s treatment with bronchodilators and inhaled GCS.

Inhaled GCS: ALMONT can be indicated as adjunctive therapy for patients with bronchial asthma for whom inhaled GCS and short-acting beta-adrenomimetics do not provide adequate clinical control. ALMONT should not be abruptly replaced by treatment with inhaled GCS.

A different dosage form of the drug, chewable tablets, is available to treat patients from 2 to 15 years of age.

Interaction

Special Instructions

Contraindications

Side effects

Overdose

Similarities